Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. [electronic resource]
Producer: 20200803Description: 33-44 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzimidazoles -- administration & dosage
- Carbamates -- administration & dosage
- Diarrhea -- chemically induced
- Disease-Free Survival
- Female
- Humans
- Male
- Melanoma -- drug therapy
- Middle Aged
- Mutation
- Nausea -- chemically induced
- Outcome Assessment, Health Care -- methods
- Prognosis
- Proto-Oncogene Proteins B-raf -- genetics
- Skin Neoplasms -- drug therapy
- Sulfonamides -- administration & dosage
- Vemurafenib -- administration & dosage
- Vomiting -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.